

Filed on behalf of Patent Owners Genentech, Inc. and City of Hope by:

David L. Cavanaugh
Reg. No. 36,476
Heather M. Petruzzi
Reg. No. 71,270
Robert J. Gunther, Jr.
Pro Hac Vice Application
Pending
Wilmer Cutler Pickering
Hale and Dorr LLP
1875 Pennsylvania Ave., NW
Washington, DC 20006

Adam R. Brausa
Reg. No. 60,287
Daralyn J. Durie
Pro Hac Vice Application
Pending
Durie Tangri LLP
217 Leidesdorff Street
San Francisco, CA 94111

Jeffrey P. Kushan
Reg. No. 43,401
Peter S. Choi
Reg. No. 54,033
Sidley Austin LLP
1501 K Street, N.W.
Washington, D.C.
20005

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SANOFI-AVENTIS U.S. LLC AND
REGENERON PHARMACEUTICALS, INC.,
Petitioners

v.

GENENTECH, INC. AND CITY OF HOPE
Patent Owners

Case IPR2015-01624
Patent 6,331,415

EXPERT DECLARATION OF JOHN FIDDES, PH.D.

MERCK v. GENENTECH

TABLE OF CONTENTS

	Page
I. INTRODUCTION AND BACKGROUND	1
A. Qualifications And Experience	2
B. Compensation	4
C. Prior Expert Testimony.....	4
II. LEGAL PRINCIPLES ON OBVIOUSNESS.....	4
III. BACKGROUND OF THE TECHNOLOGY	7
A. Genes, Proteins And Antibodies	7
B. Antibody Production Techniques As Of April 1983.....	16
C. Use of Recombinant Gene Expression To Produce Proteins.....	18
1. Basic principles of recombinant gene expression.....	18
2. As of April 1983, Only a Small Number of Monomeric Eukaryotic Proteins Had Been Produced Recombinantly.....	20
D. As of April 1983, Insulin Was The Only Multimeric Eukaryotic Protein Which Had Been Produced Recombinantly	29
E. In May 1981 (When Bujard Was Filed), The Speculative Possibility Of Using Recombinant Techniques To Produce Antibodies Was Highly Uncertain And Unpredictable	37
F. Research Involving Antibodies And Recombinant Gene Expression Between May 1981 And April 1983 Confirmed The Uncertainty And Unpredictability Of Whether Antibodies Could Be Produced Recombinantly.....	41
G. As Of April 1983, Highly Acclaimed Scientists Were Still Uncertain Whether It Was Even Possible To Make Antibodies Using Recombinant Techniques.....	46

H.	As Of April 1983, Nobody Had Produced An Antibody Recombinantly	49
I.	As Of April 1983, Nobody Had Produced A Multimeric Eukaryotic Protein Recombinantly In A Single Host Cell.....	49
IV.	THE CLAIMS UNDER CONSIDERATION AND THEIR INTERPRETATION.....	53
A.	The Cabilly '415 Patent.....	53
B.	Summary Of Contested Claims.....	54
C.	The Person Of Ordinary Skill In The Art.....	56
V.	OPINIONS REGARDING THE ASSERTED PRIOR ART	57
A.	Bujard.....	58
1.	What is the focus of the Bujard reference?	58
2.	Do the references to “multimers” and “one or more structural genes” in Bujard suggest the use of the co-expression of multiple, distinct eukaryotic genes of interest in a single host cell?	63
3.	Do the references to multiple “stop codons” in Bujard suggest the use of the strong promoter/terminator system for the expression of multiple, distinct genes in a single host cell?	72
4.	Does Bujard “at least suggest the coexpression of the heavy and light chains” of an immunoglobulin in a “single host cell,” as the Board found?	75
5.	Does Bujard “teach away from the production of light chains in one culture and heavy chains in another, to be combined chemically at a stage after their harvest and isolation,” as Dr. Foote argues?.....	79
6.	Does the statement in Bujard that the “proteins may be prepared as a single unit or as individual subunits and then joined	

together in appropriate ways” suggest in vivo assembly of a multimeric protein in a single host cell, as Dr. Foote argues?. 84

7.	Do you agree with the Board’s finding that Bujard is “more specific and robust” than the Axel reference?	86
B.	Riggs & Itakura.....	88
1.	What is the focus of the Riggs & Itakura reference?	88
2.	Does the Riggs & Itakura reference address the “same problem” as Bujard and would the skilled artisan have had “good reason” to combine these two references in April 1983?	89
3.	Would inferences gleaned from Riggs & Itakura have provided the person of ordinary skill with the motivation to “selectively apply the teachings of Bujard to the specific production of immunoglobulins” by means of co-expressing both the heavy and light chain in a single host cell?	91
4.	Do you agree with Dr. Foote’s opinion and the Board’s preliminary finding that Bujard in combination with Riggs & Itakura renders the claimed invention of the Cabilly ’415 patent obvious?.....	98
C.	Southern.....	100
1.	What is the focus of the Southern reference?	100
2.	Do you agree with Dr. Foote’s opinion that the skilled artisan would have been motivated to combine Bujard and Southern because “both have as a goal the expression of genes of interest in a single transformed host cell, whether by using one (Bujard) or two (Southern) vectors”?.....	102
3.	Would inferences gleaned from Southern have provided the person of ordinary skill with the motivation to “selectively apply the teachings of Bujard to the specific production of immunoglobulins” by means of co-expressing both the heavy and light chain in a single host cell?	104

...

1. Do you agree with Dr. Foote's opinion and the Board's preliminary finding that Bujard in combination with Southern renders the claimed invention of the Cabilly '415 patent obvious?..... 111

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.